Products
Our pipeline: Delivering first-in-class immunotherapies of activation and regulation
Three areas of expertise are being developed within our immunology research platform
- T-cell-based vaccination
- Immuno-Oncology
- Auto-Immune Diseases & Inflammation
Product
Target
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Significant partnerships with Servier, Boehringer Ingelheim and Veloxis Pharmaceuticals for up to €1.6Bn in milestones (€72 M already received since 2016)
The 3 areas of expertise
Three areas of expertise are being developed within our immunology research platform:
- T-cell based vaccination
- Immuno-Oncology (focus on myeloid targets)
- Auto-Immunity & Inflammation